Survival after Definitive (Chemo)Radiotherapy in Esophageal Cancer Patients: A Population-Based Study in the North-East Netherlands

Justin K. Smit, Christina T. Muijs, Johannes G. M. Burgerhof, Gabriel Paardekooper, Paul R. Timmer, Karin Muller, Dankert Woutersen, Veronique E. Mul, Jannet C. Beukema, Geke A. P. Hospers, Boukje A. C. van Dijk, Johannes A. Langendijk, John Th. M. Plukker*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

19 Citations (Scopus)

Abstract

Definitive (chemo)radiotherapy is employed in esophageal cancer patients as an alternative for patients considered medically unfit for surgery or having unresectable tumors. We evaluated a population-based cohort to improve the selection for intensified nonsurgical strategies and to identify prognostic factors.

Patients who had squamous cell carcinoma (SCC) or adenocarcinoma (AC) were treated in four referral centers in the north-east Netherlands with definitive chemoradiotherapy (dCRT) or radiotherapy (dRT) between 1996 and 2008.

Of the 287 included patients, 110 were treated with dCRT and 177 with dRT. Median overall survival (OS) was 11 months (95 % confidence interval: 10-12 months), with OS of 22 and 8 % and disease-free survival (DFS) of 16 and 5 % at 2 and 5 years, respectively. DFS at 2 and 5 years was 24 and 9 % for SCC versus 10 and 2 % for AC patients (P = 0.006). OS after 2 and 5 years was 29 and 14 % for SCC patients versus 17 and 3 % for AC patients (P = 0.044). On multivariate Cox regression, SCC was an independent prognostic factor for DFS [P = 0.020, hazard ratio (HR) = 0.71] and OS (P = 0.047, HR = 0.76). On matched cohort analysis, DFS was higher in the dCRT group compared with dRT patients (P = 0.016). The locoregional failure rate was lower in the dCRT group and in SCC patients (P = 0.001 and 0.046).

Long-term results and the local control rate in SCC patients were better after definitive (chemo)radiotherapy compared with in AC patients. SCC was an independent prognostic factor for survival. Definitive chemoradiotherapy leads to improved local control rate and DFS.

Original languageEnglish
Pages (from-to)1985-1992
Number of pages8
JournalAnnals of Surgical Oncology
Volume20
Issue number6
DOIs
Publication statusPublished - Jun-2013
EventEndocrine Cancer Parallel Session at the 65th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO) / Presidential Plenary Session -
Duration: 21-Mar-201224-Mar-2012

Keywords

  • PHASE-III TRIAL
  • SQUAMOUS-CELL CARCINOMA
  • NEOADJUVANT CHEMORADIOTHERAPY
  • PERIOPERATIVE CHEMOTHERAPY
  • RADIATION-THERAPY
  • RESECTABLE CANCER
  • ONCOLOGY-GROUP
  • SURGERY
  • METAANALYSIS
  • ADENOCARCINOMA

Cite this